Company intelligence / Profile preview
Therabest
- Ownership
- Private
- Development stage
- Other
Overview
Therabest is a clinical-stage biotech company developing next-generation immunotherapies using proprietary platforms based on iPSC-derived immune cells and nano-convergent drug delivery. Its lead programs include enhanced NK cell therapies for oncology and neurodegenerative diseases, with the most advanced asset in Phase 2 trials for atopic dermatitis. The company has demonstrated preclinical efficacy in solid tumors and Alzheimer’s disease models, with ongoing collaborations to expand into exosome-based therapies.[1][3][5]
- Therapeutic areas
- OncologyDermatologyGastroenterologyNeurology
- Modalities
- iPSC-derived immune cells (notably NK cells)CAR-NK cell therapyImmune cell therapyNano-convergence integrated therapeutics (nanoDDS)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Therabest.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Therabest.